The XIENCE V everolimus eluting coronary stent system takes the market-leading MULTI-LINK VISION stent and combines it with an effective drug, everolimus. This drug helps prevent narrowing of the artery within the stent.

Don't trust your heart to just any stent

In a clinical study comparing XIENCE V with TAXUS, patients who received a XIENCE V stent had:

  • 44% fewer major adverse cardiac events 2 years after stent implantation*
  • Much less renarrowing in the arteries where the stent was placed†

How XIENCE V works

The XIENCE V system consists of a cobalt chromium stent with a thin coating of drug, everolimus, on its surface. The stent gives support to the artery while the fluorinated copolymer facilitates the controlled release of everolimus into the artery wall. The release of drug is intended to limit the overgrowth of normal tissue after the stent is implanted. Overgrowth of normal tissue is thought to be a major factor in renarrowing of the artery after stenting.

The XIENCE V stent is designed to prevent narrowing within the stent.

When the XIENCE V stent system should not be used (contraindicated)

  • If you have a known allergy or contraindication to everolimus or other compounds such as cobalt, chromium, nickel, tungsten, acrylic, and fluoropolymers
  • If you cannot take aspirin or blood-thinning medications (also called antiplatelet or anticoagulant therapy)
  • If the physician decides that the blockage will not allow complete inflation of the angioplasty balloon or proper placement of the stent
Want more information on the XIENCE V stent system?

See how XIENCE V works inside a vessel

Download the Patient Information Guide

Learn about the XIENCE V procedure>

*Source: SPIRIT III 2 year results, Gregg Stone, PCR 2008.

†XIENCE V Patient Information Guide.

TAXUS, TAXUS Liberte, TAXUS Express2 are registered trademarks of Boston Scientific and its affiliates.